1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: CNS Biomarkers Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. CNS Biomarkers Market, by Biomarker Type
8.1.1. Protein Biomarkers
8.1.1.1. Market Revenue and Forecast
8.1.2. Genetic Biomarkers
8.1.2.1. Market Revenue and Forecast
8.1.3. Metabolic Biomarkers
8.1.3.1. Market Revenue and Forecast
8.1.4. Imaging Biomarkers
8.1.4.1. Market Revenue and Forecast
8.1.5. Cellular Biomarkers
8.1.5.1. Market Revenue and Forecast
9.1. CNS Biomarkers Market, by Technology
9.1.1. Immunoassays
9.1.1.1. Market Revenue and Forecast
9.1.2. Molecular Diagnostics
9.1.2.1. Market Revenue and Forecast
9.1.3. Proteomics
9.1.3.1. Market Revenue and Forecast
9.1.4. Genomics
9.1.4.1. Market Revenue and Forecast
9.1.5. Neuroimaging Technologies
9.1.5.1. Market Revenue and Forecast
10.1. CNS Biomarkers Market, by Application
10.1.1. Alzheimers Disease
10.1.1.1. Market Revenue and Forecast
10.1.2. Parkinsons Disease
10.1.2.1. Market Revenue and Forecast
10.1.3. Multiple Sclerosis
10.1.3.1. Market Revenue and Forecast
10.1.4. Epilepsy
10.1.4.1. Market Revenue and Forecast
10.1.5. Traumatic Brain Injury (TBI)
10.1.5.1. Market Revenue and Forecast
10.1.6. Stroke
10.1.6.1. Market Revenue and Forecast
10.1.7. Psychiatric Disorders
10.1.7.1. Market Revenue and Forecast
10.1.8. Other Neurological Disorders
10.1.8.1. Market Revenue and Forecast
11.1. CNS Biomarkers Market, by Sample Type
11.1.1. Blood
11.1.1.1. Market Revenue and Forecast
11.1.2. Cerebrospinal Fluid
11.1.2.1. Market Revenue and Forecast
11.1.3. Urine
11.1.3.1. Market Revenue and Forecast
11.1.4. Saliva
11.1.4.1. Market Revenue and Forecast
11.1.5. Brain Imaging Data
11.1.5.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Biomarker Type
12.1.2. Market Revenue and Forecast, by Technology
12.1.3. Market Revenue and Forecast, by Application
12.1.4. Market Revenue and Forecast, by Sample Type
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Biomarker Type
12.1.5.2. Market Revenue and Forecast, by Technology
12.1.5.3. Market Revenue and Forecast, by Application
12.1.5.4. Market Revenue and Forecast, by Sample Type
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Biomarker Type
12.1.6.2. Market Revenue and Forecast, by Technology
12.1.6.3. Market Revenue and Forecast, by Application
12.1.6.4. Market Revenue and Forecast, by Sample Type
12.2. Europe
12.2.1. Market Revenue and Forecast, by Biomarker Type
12.2.2. Market Revenue and Forecast, by Technology
12.2.3. Market Revenue and Forecast, by Application
12.2.4. Market Revenue and Forecast, by Sample Type
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Biomarker Type
12.2.5.2. Market Revenue and Forecast, by Technology
12.2.5.3. Market Revenue and Forecast, by Application
12.2.5.4. Market Revenue and Forecast, by Sample Type
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Biomarker Type
12.2.6.2. Market Revenue and Forecast, by Technology
12.2.6.3. Market Revenue and Forecast, by Application
12.2.6.4. Market Revenue and Forecast, by Sample Type
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Biomarker Type
12.2.7.2. Market Revenue and Forecast, by Technology
12.2.7.3. Market Revenue and Forecast, by Application
12.2.7.4. Market Revenue and Forecast, by Sample Type
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Biomarker Type
12.2.8.2. Market Revenue and Forecast, by Technology
12.2.8.3. Market Revenue and Forecast, by Application
12.2.8.4. Market Revenue and Forecast, by Sample Type
12.3. APAC
12.3.1. Market Revenue and Forecast, by Biomarker Type
12.3.2. Market Revenue and Forecast, by Technology
12.3.3. Market Revenue and Forecast, by Application
12.3.4. Market Revenue and Forecast, by Sample Type
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Biomarker Type
12.3.5.2. Market Revenue and Forecast, by Technology
12.3.5.3. Market Revenue and Forecast, by Application
12.3.5.4. Market Revenue and Forecast, by Sample Type
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Biomarker Type
12.3.6.2. Market Revenue and Forecast, by Technology
12.3.6.3. Market Revenue and Forecast, by Application
12.3.6.4. Market Revenue and Forecast, by Sample Type
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Biomarker Type
12.3.7.2. Market Revenue and Forecast, by Technology
12.3.7.3. Market Revenue and Forecast, by Application
12.3.7.4. Market Revenue and Forecast, by Sample Type
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Biomarker Type
12.3.8.2. Market Revenue and Forecast, by Technology
12.3.8.3. Market Revenue and Forecast, by Application
12.3.8.4. Market Revenue and Forecast, by Sample Type
12.4. MEA
12.4.1. Market Revenue and Forecast, by Biomarker Type
12.4.2. Market Revenue and Forecast, by Technology
12.4.3. Market Revenue and Forecast, by Application
12.4.4. Market Revenue and Forecast, by Sample Type
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Biomarker Type
12.4.5.2. Market Revenue and Forecast, by Technology
12.4.5.3. Market Revenue and Forecast, by Application
12.4.5.4. Market Revenue and Forecast, by Sample Type
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Biomarker Type
12.4.6.2. Market Revenue and Forecast, by Technology
12.4.6.3. Market Revenue and Forecast, by Application
12.4.6.4. Market Revenue and Forecast, by Sample Type
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Biomarker Type
12.4.7.2. Market Revenue and Forecast, by Technology
12.4.7.3. Market Revenue and Forecast, by Application
12.4.7.4. Market Revenue and Forecast, by Sample Type
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Biomarker Type
12.4.8.2. Market Revenue and Forecast, by Technology
12.4.8.3. Market Revenue and Forecast, by Application
12.4.8.4. Market Revenue and Forecast, by Sample Type
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Biomarker Type
12.5.2. Market Revenue and Forecast, by Technology
12.5.3. Market Revenue and Forecast, by Application
12.5.4. Market Revenue and Forecast, by Sample Type
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Biomarker Type
12.5.5.2. Market Revenue and Forecast, by Technology
12.5.5.3. Market Revenue and Forecast, by Application
12.5.5.4. Market Revenue and Forecast, by Sample Type
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Biomarker Type
12.5.6.2. Market Revenue and Forecast, by Technology
12.5.6.3. Market Revenue and Forecast, by Application
12.5.6.4. Market Revenue and Forecast, by Sample Type
13.1. F. Hoffmann-La Roche Ltd.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Thermo Fisher Scientific
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Bio-Rad Laboratories
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Quanterix Corporation
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Siemens Healthineers
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Abbott Laboratories
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. GE HealthCare
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. PerkinElmer
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Qiagen N.V.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Agilent Technologies
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
